We also observed characteristic TBC1D16 methylation changes in both melanoma and breast cancer (hypomethylation of the TBC1D16 gene body, including the cryptic TBC1D16-47KD cryptic promoter (75%), in metastatic melanoma compared to primary melanoma and also hypomethylation (94%) in metastatic vs primary paired breast cancer samples). The gene discussed is TBC1D16; the disease is metastatic melanoma.